Key market opportunities include the rising prevalence of chronic diseases and increased regulatory approvals driving demand ...

The FDA AMT designation verifies NanoMosaic platform's ability to enhance efficiency, product quality, and scalability across AAV gene therapy manufacturing.

NanoMosaic's technology is designed to support upstream and downstream process development, quality control, and release testing.

Delivers 2x increase in AAV titers compared to market alternates. Reduce plasmid input, halve the bioreactors, and significantly lower cost per dose. HORSHAM, Pa., Aug. 12, 2025 /PRNewswire/ -- In a ...

Adeno-associated viruses (AAVs) are popularly used as vectors for therapeutic applications, including cell and gene therapy approaches. As such, AAV characterization is an important element in ...

HOPEWELL, N.J., Aug. 11, 2025 /PRNewswire/ -- ProBio, a leading contract development and manufacturing organization (CDMO) specializing in gene and cell therapy, today announced the launch of its cGMP ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Diorasis Therapeutics is advancing AAV gene therapy for glaucoma treatment VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis ...

VILNIUS, LT / ACCESS Newswire / July 29, 2025 / Diorasis Therapeutics (“DTx”), a preclinical-stage biotechnology company developing gene therapies for ophthalmic diseases, has entered into a strategic ...